Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Avistone Announces Updates on ANS014004
Details : ANS01 (ANS014004) is a novel small-molecule type II c-Met tyrosine kinase inhibitor, which is being evaluated for the treatment of locally advanced or metastatic solid tumors.
Brand Name : ANS01
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 04, 2024
Lead Product(s) : Vebreltinib
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Avistone Approves Vebreltinib as First MET-TKI Treatment for Rare Glioma Subtype in China
Details : APL-101 (vebreltinib) is a highly specific cMet inhibitor which is indicated for the treatment of sGBM/IDH mutant glioblastoma with the ZM fusion gene.
Brand Name : PLB1001
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 25, 2024
Lead Product(s) : Vebreltinib
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Vebreltinib
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : SDIC CS Capital
Deal Size : $140.0 million
Deal Type : Series B Financing
Avistone Biotechnology Announces Closing of Series B Financing
Details : The net proceeds will be used to support clinical research and development of the Avistone pipeline, including PLB1001 (vebreltinib), a small-molecule inhibitor targeting MET tyrosine kinase activity.
Brand Name : PLB1001
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 04, 2024
Lead Product(s) : Vebreltinib
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : SDIC CS Capital
Deal Size : $140.0 million
Deal Type : Series B Financing
LOOKING FOR A SUPPLIER?
Reset All
